Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray.

Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray.

Publication date: Jan 18, 2024

The capability of antibodies to neutralize different SARS-CoV-2 variants varies among individuals depending on the previous exposure to wild-type or Omicron-specific immunogens by mono- or bivalent vaccinations or infections. Such profiles of neutralizing antibodies (nAbs) usually have to be assessed via laborious live-virus neutralization tests (NTs). We therefore analyzed whether a novel multivariant surrogate-virus neutralization test (sVNT) (adapted from a commercial microarray) that quantifies the antibody-mediated inhibition between the receptor angiotensin-converting enzyme 2 (ACE2) and variant-specific receptor-binding domains (RBDs) can assess the neutralizing activity against the SARS-CoV-2 wild-type, and Delta Omicron BA. 1, BA. 2, and BA. 5 subvariants after a booster with Omicron-adapted bivalent vaccines in a manner similar to live-virus NTs. Indeed, by using the live-virus NTs as a reference, we found a significant correlation between the variant-specific NT titers and levels of ACE2-RBD binding inhibition (p < 0. 0001, r ≤ 0. 78 respectively). Furthermore, the sVNTs identified higher inhibition values against BA. 5 and BA. 1 in individuals vaccinated with Omicron-adapted vaccines than in those with monovalent wild-type vaccines. Our data thus demonstrate the ability of sVNTs to detect variant-specific nAbs following a booster with bivalent vaccines.

Open Access PDF

Concepts Keywords
Ace2 assay
Immunogens bivalent vaccination
Laborious neutralization
Live Omicron
Microarray SARS-CoV-2
surrogate

Semantics

Type Source Name
disease MESH infections
drug DRUGBANK Angiotensin II
disease VO vaccinated
disease VO vaccination
disease IDO assay
disease VO vaccine
drug DRUGBANK Gold
drug DRUGBANK Coenzyme M
disease IDO infection
disease VO protocol
drug DRUGBANK Alkaline Phosphatase
disease VO titer
drug DRUGBANK Saquinavir
disease VO unvaccinated
disease MESH SARS CoV 2 infection
disease VO dose
disease VO vaccine dose
disease VO vaccine efficacy
disease VO population
disease IDO history
drug DRUGBANK Cyclic Adenosine Monophosphate
drug DRUGBANK Serine
disease VO immunization
disease MESH breakthrough infection
disease VO effectiveness
disease IDO host

Original Article

(Visited 1 times, 1 visits today)